Evidence map›Paper›PMID 33586090›Full record

Trial reportJapanese journal of ophthalmology2021

Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study.

Osamu Hieda, Takahiro Hiraoka, Takashi Fujikado, Satoshi Ishiko, Satoshi Hasebe, Hidemasa Torii, Hiroshi Takahashi, Yo Nakamura, Chie Sotozono, Tetsuro Oshika and 16 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Japanese journal of ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 12 pooled it
15.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 12 syntheses or guidelines pooled it, 132 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Effect of low-dose atropine eyedrops on pupil metrics: results after half a year of treatment and cessation.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023
    Trial

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 7 institutions in 2 countries.

Osamu HiedaDepartment of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan.
Takahiro HiraokaDepartment of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tusukuba, Ibaraki, Japan.
Takashi FujikadoGraduate School of Frontier Biosciences, Osaka University, Suita, Osaka, Japan.
Satoshi IshikoDepartment of Ophthalmology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
Satoshi HasebeDepartment of Ophthalmology 2, Kawasaki Medical School, Kurashiki, Okayama, Japan.
Hidemasa ToriiDepartment of Ophthalmology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Hiroshi TakahashiDepartment of Ophthalmology, Nippon Medical School, Bunkyo-ku, Tokyo, Japan.
Yo NakamuraDepartment of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan.
Chie SotozonoDepartment of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan.
Tetsuro OshikaDepartment of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tusukuba, Ibaraki, Japan.
Takeshi MorimotoDepartment of Advanced Visual Neuroscience, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Kohji NishidaDepartment of Ophthalmology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Noriko NishikawaDepartment of Ophthalmology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
Young-Seok SongDepartment of Ophthalmology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
Tomoki TokutakeDepartment of Ophthalmology, Kawasaki Medical School General Medical Center, Okayama, Okayama, Japan.
Yasuyo NishiDepartment of Ophthalmology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Yuta ShigenoDepartment of Ophthalmology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Toshihide KuriharaDepartment of Ophthalmology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Kazuno NegishiDepartment of Ophthalmology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Kazuo TsubotaDepartment of Ophthalmology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Masafumi OnoDepartment of Ophthalmology, Nippon Medical School, Bunkyo-ku, Tokyo, Japan.
Tomoko NakaiClinical Biostatistics Course, School of Public Health, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan.
Donald TanSingapore National Eye Centre, Singapore, Singapore.
Shiro TanakaClinical Biostatistics Course, School of Public Health, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan.
Shigeru KinoshitaDepartment of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, Kyoto, 602-0841, Japan. shigeruk@koto.kpu-m.ac.jp.
ATOM-J. Study Group
Keio University · JPAsahikawa Medical University · JPKyoto Prefectural University of Medicine · JPKyoto University · JPUniversity of Tsukuba · JPKawasaki Medical School · JPThe University of Osaka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAtropine eye drops prevent the progression of myopia, but their use has not been tested in the Japanese schoolchildren population. Here, we evaluate the efficacy and safety of 0.01% atropine eye drops for myopia control in Japanese children. STUDY

designMulticenter (7 university hospitals), randomized, double-masked, placebo-controlled trial.

methodsParticipants were 171 Japanese schoolchildren aged 6 to 12 years, with progressive myopia, spherical equivalence (SE) of -1.00 to -6.00 diopters (D), and astigmatism of ≤1.5 D. They were randomized to receive either 0.01% atropine (n=85) or placebo (n=86) eye drops once nightly OU for 24 months. Primary and secondary efficacy endpoints were changes in SE and axial length (AL), respectively, from baseline to month 24.

resultsData from 168 subjects were analyzed. At month 24, compliance was similar in both groups (atropine: 83.3%; placebo: 85.7%). The least squares mean change in SE and AL from baseline were, respectively, -1.26 D (95% confidence interval [CI]: -1.35, -1.17) and 0.63 mm (0.59, 0.67) for atropine and -1.48 D (- 1.57, -1.39) and 0.77 mm (0.73, 0.81) for placebo. Inter-group differences were 0.22 D (95% CI: 0.09, 0.35; P < 0.001) for SE and - 0.14 mm (-0.20, -0.08; P < 0.001) for AL. Three patients experienced mild allergic conjunctivitis side effects, with no inter-group difference in incidence (atropine: 2.4%; 2/84 patients; placebo: 1.4%; 1/84 patients).

conclusionWith good compliance, 0.01% atropine is effective and safe for preventing the progression of childhood myopia.

Indexed as

AtropineMyopia, DegenerativeAccommodation, OcularChildDisease ProgressionHumansOphthalmic SolutionsRefraction, OcularVisual AcuityAtropineOphthalmic SolutionsEye dropMuscarinic receptorMyopia controlPlaceboSchool children

Identifiers

PMID33586090
OpenAlexW3131578737

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.